Form 4: ADMA Biologics Director Exercises and Sells Shares Ahead of Option Expiration

ADMA Biologics Director Lawrence P. Guiheen executed a series of transactions, exercising stock options and subsequently selling the acquired common stock for a significant profit, while maintaining a substantial beneficial ownership.

Summary

• Lawrence P. Guiheen, a Director of ADMA Biologics, Inc., engaged in stock option exercises and subsequent sales of common stock on May 21 and May 22, 2025.
• On May 21, 2025, Mr. Guiheen exercised options to acquire 7,779 shares of common stock at an exercise price of $5.96 per share.
• Immediately following the exercise on May 21, 2025, he sold all 7,779 shares at a weighted average price of $20.32 per share, with prices ranging from $20.20 to $20.73.
• On May 22, 2025, Mr. Guiheen exercised options to acquire an additional 1,221 shares of common stock at an exercise price of $5.96 per share.
• Concurrently on May 22, 2025, he sold all 1,221 shares at a price of $20.12 per share.
• The options exercised were granted on January 28, 2016, fully vested by January 28, 2018, and were nearing their expiration date of January 28, 2026.
• Following these transactions, Mr. Guiheen directly beneficially owns 114,830 shares of common stock, which includes 10,889 restricted stock units vesting in two installments on August 19, 2025, and February 19, 2026, and 103,941 shares of common stock.
• Additionally, 50,990 shares of common stock are held indirectly through the Lawrence P Guiheen Irrevocable Trust 1.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, this transaction appears to be a routine exercise of expiring options and subsequent sale for profit, which is a common and expected financial planning activity for executives. The director retains a significant beneficial ownership, both directly and indirectly, which mitigates strong negative sentiment.

Positives

• The director realized a significant profit from exercising options at $5.96 and selling shares at prices between $20.12 and $20.73.
• The transactions demonstrate the director's ability to monetize long-held stock options.
• The director continues to hold a substantial number of shares directly and indirectly, indicating continued alignment with shareholder interests.

Negatives

• The sale of shares by a director could be perceived negatively by some investors, as it reduces insider ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as its purpose is solely to report insider transactions.

Management Comments

• "The Reporting Person is exercising this option due, in part, to its near-term expiration date."
• "The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context. However, insider sales can sometimes be observed in the biotechnology or pharmaceutical industry, where executives may monetize equity compensation after periods of stock appreciation or as part of personal financial planning.

Comparison to Industry Standards

• This document reports specific insider transactions for ADMA Biologics and does not provide data for direct comparison to industry-wide benchmarks or specific competitor transactions.
• Insider trading patterns vary widely across companies and individuals, making direct comparisons without broader context difficult. However, the exercise of options nearing expiration and subsequent sale is a common practice for executives managing their equity compensation.

Related Party Transactions

• 50,990 shares of common stock are held indirectly in the Lawrence P Guiheen Irrevocable Trust 1, which is a related party transaction as it is controlled by the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted as a signal, but given it's an option exercise and sale, it's likely for personal financial planning. The director still holds a substantial stake, indicating continued alignment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The remaining 10,889 restricted stock units held by the reporting person are scheduled to vest in two equal installments on August 19, 2025, and February 19, 2026.

Key Dates

Recommendation

Keywords

ADMA Biologics, ADMA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transactions, Beneficial Ownership, SEC Filing, Equity Compensation